Antonio Lavecchia

Prof. Antonio Lavecchia

University of Naples Federico II - Department of Pharmacy
orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2015 in Drug Discovery Today
Verified
Journal Article
Closed access
Antonio LavecchiaAntonio Lavecchia
Antonio Lavecchia

1 June 2013 in Current Medicinal Chemistry
Verified
Journal Article
Closed access
Antonio LavecchiaAntonio Lavecchia
Antonio Lavecchia
Carmen Di GiovanniCarmen Di Giovanni
Carmen Di Giovanni
Virtual screening (VS) is a powerful technique for identifying hit molecules as starting points for medicinal chemistry. The number of methods and softwares which use the ligand and target-based VS approaches is increasing at a rapid pace. What, however, are the real advantages and disadvantages of the VS technology and how applicable is it to drug discovery projects? This review provides a comprehensive appraisal of several VS approaches currently available. In the first part of this work, an overview of the recent progress and advances in both ligand-based VS (LBVS) and structurebased VS (SBVS) strategies highlighting current problems and limitations will be provided. Special emphasis will be given to in silico chemogenomics approaches which utilize annotated ligand-target as well as protein-ligand interaction databases and which could predict or reveal promiscuous binding and polypharmacology, the knowledge of which would help medicinal chemists to design more potent clinical candidates with fewer side effects. In the second part, recent case studies (all published in the last two years) will be discussed where the VS technology has been applied successfully. A critical analysis of these case studies provides a good platform in order to estimate the applicability of various VS strategies in the new lead identification and optimization.

1 October 2019 in Drug Discovery Today
Verified
Journal Article
Closed access
Antonio LavecchiaAntonio Lavecchia
Antonio Lavecchia

1 February 2016 in Drug Discovery Today
Verified
Journal Article
Closed access
Antonio LavecchiaAntonio Lavecchia
Antonio Lavecchia
Carmen CerchiaCarmen Cerchia
Carmen Cerchia

12 May 2007 in Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
GRGiuseppe La Regina
Giuseppe La Regina
MEMichael C. Edler
Michael C. Edler
ABAndrea Brancale
Andrea Brancale
Sahar B. KandilSahar B. Kandil
Sahar B. Kandil
ACAntonio Coluccia
Antonio Coluccia
RSRomano Silvestri
Romano Silvestri

23 April 2024 in Drug Discovery Today
Verified
Journal Article
Open access
AGAmit Gangwal
Amit Gangwal
Antonio LavecchiaAntonio Lavecchia
Antonio Lavecchia
Artificial intelligence (AI) is revolutionizing drug discovery by enhancing precision, reducing timelines and costs, and enabling AI-driven computer-aided drug design. This review focuses on recent advancements in deep generative models (DGMs) for de novo drug design, exploring diverse algorithms and their profound impact. It critically analyses the challenges that are intricately interwoven into these technologies, proposing strategies to unlock their full potential. It features case studies of both successes and failures in advancing drugs to clinical trials with AI assistance. Last, it outlines a forward-looking plan for optimizing DGMs in de novo drug design, thereby fostering faster and more cost-effective drug development.